The search for an efficacious human immunodeficiency virus type 1 (HIV-1) vaccine remains a pressing need. The moderate success of the RV144 Thai clinical vaccine trial suggested that vaccine-induced HIV-1-specific antibodies can reduce the risk of HIV-1 infection. We have made several improvements to the DNA platform and have previously shown that improved DNA vaccines alone are capable of inducing both binding and neutralizing antibodies in small-animal models. In this study, we explored how an improved DNA prime and recombinant protein boost would impact HIV-specific vaccine immunogenicity in rhesus macaques (RhM). After DNA immunization with either a single HIV Env consensus sequence or multiple constructs expressing HIV subtype-specific Env consensus sequences, we detected both CD4
T o prevent human immunodeficiency virus (HIV) infection, a vaccine will likely need to induce antibodies with a broad range of binding and Fc-mediated functions, including antibodydependent cellular cytotoxicity (ADCC) in addition to virus neutralization. The induction of broad multifunctional antibody responses with an HIV vaccine in nonhuman primates (NHPs) has been challenging. Previous studies of neutralizing antibodies have focused on rare tier 1 HIV-1 viruses that are relatively easy to neutralize due to the difficulty in inducing neutralizing responses against the more common tier 2 HIV-1 isolates (1, 2) . Current vaccines using a nucleic acid prime followed by a protein or viral vector boost usually induce either no or only minimal neutralizing antibodies after the priming immunizations and require one or more boosts to induce substantial titers (3) (4) (5) (6) (7) (8) (9) .
It has also been reported that vaccine-induced nonneutralizing Fc-mediated antibody functions could be important in providing protection from HIV-1 infection (10) . Among these functions, ADCC has been reported to play a relevant role in control. In fact, several studies have correlated protection from simian immuno-deficiency virus (SIV) and simian-human immunodeficiency virus (SHIV) infection with the presence of ADCC activity (11) (12) (13) . Moreover, in the ALVAC/AIDSVax RV144 clinical trial, which provided a modest 31.2% protection from infection, the ADCC responses in vaccinees with low-level anti-Env plasma IgA responses correlated with a lower risk of infection (14, 15) . Additionally, in the course of natural infection, ADCC responses have been associated with a delay in disease onset, viral control, and the status of long-term nonprogressors (16) (17) (18) . In a previous study, regimens with DNA prime-modified vaccinia virus Ankara (MVA) boost, DNA prime-MVA and gp140 boost, MVA prime-MVA and gp140 boost, and four doses of gp140 alone failed to induce any ADCC activity in NHP serum (19) . However, recently it has been shown that DNA or MVA priming followed by a gp140 boost based on a transmitter founder virus (HIV C.1086) can induce ADCC activity following the protein boost (20) . Yet, it remains unclear if similar activity can be achieved by DNA-only prime or in combination with a boost containing unmatched Envs.
Though DNA has previously been relegated to a priming role due to its inability to induce strong humoral responses, many advances in the field, including the use of DNA and RNA optimization strategies as well as the use of electroporation (EP), and better formulations have increased the effectiveness of this platform in stimulating primary immune responses (21) (22) (23) (24) (25) (26) (27) . This once modest platform is now capable of inducing T-cell responses as good as or better than those induced by viral vectors (25) . Additionally, these improvements have enabled DNA to induce humoral responses in NHPs and humans. For example, in a recent phase I clinical trial, all subjects (18/18) responded to at least two vaccine antigens, according to enzyme-linked immunosorbent assays (ELISAs), after they received a DNA vaccine for human papillomavirus (HPV) (21) . Despite these advances in the immunogenicity achieved with DNA alone, improvements are still needed, especially in the induction of protective functional antibodies and increased breadth of responses. One of the strengths of DNA vaccination is the ability to include multiple Env constructs in a single injection that is easily formulated and manufactured. We have recently reported on the ability to combine multiple consensus Env immunogens to increase both humoral and cellular responses above those induced by the individual constructs in small animals (28) . The antibody responses were further boosted with protein immunization and were able to neutralize a panel of tier 1 viruses with neutralizing titers of greater magnitude than either platform alone (28) .
In this study, we further examined how an improved DNA prime capable of inducing strong antibody responses impacts the magnitude and quality of the HIV Env-specific antibody response when it is combined with an adjuvanted recombinant protein boost in rhesus macaques (RhMs). Building upon small-animal studies, we wanted to determine if increased polyvalency of Env constructs would increase the breadth of immune responses in NHPs. Compared to the single Env construct, including multiple consensus Env immunogens significantly increased cross-clade binding titers. We observed broad binding antibodies and tier 1 neutralization titers averaging 10 2 with the improved synthetic multi-Env (ME) DNA prime alone. With just a single protein boost, neutralization titers increased 10-to 100-fold, and ADCC activity was observed against SF162 virus-coated targets. Together, these data demonstrate the utility of improved synthetic ME DNA priming used in combination with protein boosts.
MATERIALS AND METHODS
Plasmids. All plasmids were RNA and codon optimized and included an IgE leader sequence for efficient transcription and translation. The inserts were all consensus immunogens created as previously described (27) (28) (29) (30) (31) (32) and cloned into the pVax backbone under the control of the human cytomegalovirus immediate early promoter/enhancer. The cytoplasmic tails of all Env antigens were truncated in order to prevent Env recycling.
Vaccination. Fourteen Indian rhesus macaques were housed at The Children's Hospital of Philadelphia (Philadelphia, PA) according to the standards of the American Association for Accreditation of Laboratory Animal Care, and all animal protocols were IACUC approved. Five animals (B group) were vaccinated at weeks 0, 6, 12, and 18 with an HIV DNA consisting of consensus plasmids expressing multiclade Gag and Pol with clade B Env. Five animals (ME group) were vaccinated at weeks 0, 6, 12, and 18 with an HIV DNA vaccine consisting of consensus plasmids expressing multiclade Gag and Pol with clade A, B, C, D, and A/E Env. All DNA was formulated in water at 1.0 mg for Gag and Pol and 1.5 mg for each Env construct. Both groups along with an additional four naive animals were boosted with 100 g of recombinant SF162 gp140 formulated in MF59 adjuvant at week 32. DNA was delivered to a single site in the quadriceps, followed by in vivo EP with a constant-current Cellectra device (Inovio Pharmaceuticals, Plymouth Meeting, PA) with three pulses at a 0.5-A constant current, a 52-ms pulse length, and 0.2-s rest between pulses. Recombinant protein was delivered in a single intramuscular (i.m.) injection.
Blood collection. Animals were bled 2 weeks following each immunization. Blood (20 ml at each time point) was collected in EDTA tubes, and peripheral blood mononuclear cells (PBMCs) were isolated using a standard Ficoll-Hypaque procedure with Accuspin tubes (Sigma-Aldrich, St. Louis, MO).
Intracellular staining of PBMCs. Intracellular staining of PBMCs was performed as previously described (26) . Briefly, after isolation, PBMCs (1 to 2 ϫ 10 6 ) were stimulated with individual pools of either Gag, Pol, or Env A, B, C, or D for 6 h in a 96-well U-bottom plate. Each peptide pool contained approximately 1 g of each peptide. Medium only (R10) and phorbol myristate acetate (PMA; 0.1 g/ml) plus ionomycin (0.5 g/ml) were used as negative and positive controls, respectively. All stimulations were performed in the presence of the secretion inhibitors brefeldin A (1 g/ml; BD Biosciences, San Jose, CA) and monensin (1 g/ml; BD Biosciences). After stimulation, cells were washed with phosphate-buffered saline (PBS) and stained with the violet amine-reactive dye Live/Dead stain (Life Technologies, Carlsbad, CA) for 5 min, followed by surface staining for 30 min at room temperature. Cells were washed with PBS and fixed/permeabilized with BD Cytofix/Cytoperm (BD Biosciences) for 15 min at room temperature. Following washing with BD Perm/Wash buffer, cells were stained with intracellular antibodies for 1 h at room temperature, washed, and fixed with 2% paraformaldehyde. Cells were analyzed using a modified BD LSR II (BD Biosciences), and analysis was performed with FlowJo, version 9.2 (Tree Star, Ashland, OR).
Endpoint binding ELISA. The ELISA was performed as previously described using 1 g/ml HIV consensus clade A, B, or C gp120 (Immune Technology Corp., New York, NY) in PBS with 0.5% Tween 20 (PBS-T) (33) . Endpoint titers were determined as previously reported (34) . Briefly, the upper prediction limit of HIV-specific IgG antibodies was calculated using the Student t distribution, where the mathematical formula that defines the upper prediction limit is expressed as the standard deviation multiplied by a factor based on the number of naive controls and a 95% confidence interval. The endpoint titer is reported as the reciprocal of the lowest dilution that remained above the upper prediction limit.
Multi-Env binding ELISA. A protocol similar to that described above was used to determine binding specificity against multiple different Envs. Briefly, plates were coated with 1 g/ml of each of the specific Envs: ZM197, A244, 92RW020, HXBC2, TRJO455, SF162, and gp41 (HXBC2) (Immune Technology Corp., New York, NY) in PBS. After a blocking step, serum samples from prebleed, 2 weeks post-final DNA immunization, or 2 weeks post-final protein immunization were diluted 1:50 in 1% fetal bovine serum (FBS) in PBS-T and allowed to incubate for 1 h at room temperature. Mouse anti-NHP IgG-horseradish peroxidase (HRP) (Southern Biotech, Birmingham, AL) at a 1:5,000 dilution in 1% FBS in PBS-T was used. Plates were then developed using SigmaFast o-phenylenediamine dihydrochloride (OPD) tablets according to the manufacturer's instructions (Sigma-Aldrich, St. Louis, MO). The reaction was stopped after 15 min with the addition of 2N H 2 SO 4 . Plates were then read at an optical density of 450 nm (OD 450 ) on a GloMax 96 Microplate Luminometer (Promega, Madison, WI). All samples were plated in duplicate.
V1/V2 and V3 binding specificity ELISA. Cyclic V1/V2 or V3 binding specificity was determined as previously described (35) . Briefly, plates were coated with 1 g/ml cyclic V1/V2 and V3 constructs and incubated at 37°C for 1.5 h. After plates were washed with 1ϫ PBS-T, serum samples from prebleed, week 20 (post-final DNA immunization), and week 34 (post-protein boost) were diluted 1:35 and incubated for 1.5 h at 37°C. Secondary anti-human alkaline phosphatase-conjugated antibody (Ab) (Southern Biotech, Birmingham, AL) was diluted 1:2,000 and incubated for 1.5 h at 37°C. After plates were washed, they were developed with para-nitrophenyl phosphate (pNPP) substrate (1 mg/ml in 10% diethanolamine) and incubated for 30 min at room temperature. Plates were then read at the OD 405 .
Individual peptide mapping. Overlapping 15-mer peptides were obtained from the NIH AIDS Reagent Program for consensus clade C HIVgp160 (catalog number 9499). Peptides were resuspended in PBS to obtain a concentration of 1 mg/peptide in 1 ml. Plates were coated with 1 g/ml of peptide, and an ELISA was performed as described above.
Avidity index ELISA. The avidity of the humoral responses was assessed against consensus clade A, B, and C gp120 at 2 weeks after each DNA vaccination for the ME group and at 2 and 11 weeks after protein boost for clade B DNA-only, ME DNA, and protein-only groups. Plates were coated with 1 g/ml of either consensus clade A, B, or C gp120 (Immune Technology Corp., New York, NY) in PBS. After a blocking step, serum was diluted to 1:50 or, for the dilution curves, 1:50 and then 4-fold from there in 1% FBS in PBS-T. Each sample was run in quadruplicate with half of the wells treated and half left untreated. After a 1-h incubation, plates were washed five times with PBS-T. Half of the wells for each sample were incubated with denaturing reagent (8 M urea) for 5 min while the others were incubated with PBS. Plates were washed and incubated with mouse anti-NHP IgG-HRP (Southern Biotech, Birmingham, AL) at a 1:5,000 dilution in 1% FBS in PBS-T. Plates were then developed as described above, and the OD 450 values were obtained. The avidity index was determined by dividing the OD 450 values of the treated samples by those of the untreated samples and multiplying by 100.
Neutralization. Neutralization was determined using a previously described TZM-bl based assay (2) . Briefly, pseudotyped viruses were produced by transfecting 293T cells with plasmids expressing HIV env and env-deficient HIV-1 backbone plasmid (pSG3⌬Env) using FuGene6 (Promega, Madison, WI). Medium containing viruses was collected 48 h after transfection, spun, and cleared through a 0.45-m-pore-size filter. Viral titers were then determined to calculate the tissue culture infective dose (TCID) at which infectivity produced 150,000 relative luminescence units (RLU). For neutralization, serum was diluted 1:20 in 10% Dulbecco's modified Eagle's medium (DMEM), followed by serial 3-fold dilutions (range, 1:20 to 1:43,740) and incubated for 1 h at 37°C with virus for which the titers had been determined. TZM-bl cells were then added (1 ϫ 10 4 /well in 100 l) with DEAE-dextran with the final concentration of 10 g/ml. Controls included TZM-bl cells only and cells with virus only. Plates were incubated for 48 h at 37°C. Following incubation, 150 l of medium was removed, and 100 l of Bright-Glo luciferase reagent (Promega, Madison, WI) was added. After a 2-min lysis, 150 l of the lysate was transferred into a 96-well black solid plate, and luminescence was measured using a Victor 3 Luminometer (PerkinElmer, Waltham, MA). The 50% inhibitory dose (ID 50 ) titer was determined as the serum dilution that caused a 50% reduction in the RLU count compared to the level in the virus control after subtraction of the cell control background.
ADCC. ADCC activity against SF162-coated target cells was measured using an ADCC-GranToxiLux (GTL) assay as previously described (36) . This assay measures the percentage of target cells containing active granzyme B (GzB), a principal effector of cell-mediated cytotoxicity (37), after incubation with effector cells and serum samples. Target cells were CEM.NKR CCR5 cells (NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH; CEM.NKR-CCR5 from Alexandra Trkola) coated with recombinant HIV-1 clade B SF162 gp120 (Immune Technology Corp., New York, NY). ADCC activity against HIV-1-infected cells was measured as a percentage of target cell killing using a luciferase (Luc) ADCC assay as described previously (38) . For these assays, the CEM.NKR CCR5 target cells were infected with a replication-competent infectious molecular clone designed to encode the SF162.LS (GenBank accession number EU123924) env gene in cis within an isogenic backbone that also expresses the Renilla luciferase reporter gene and preserves all viral open reading frames (39, 40) . For both ADCC assay methodologies, the effector cells were PBMCs isolated from an HIV-1-seronegative human donor heterozygous for 158F/V polymorphic variants of Fc␥ receptor 3A. Serum was tested at baseline, at week 20 (2 weeks post-final DNA immunization), and at week 34 (2 weeks post-protein boost). Serum samples were tested using 4-fold serial dilutions ranging from 1:100 to 1:102,400. The results were calculated as maximal percent specific granzyme B (GzB; baseline sample) and percent specific killing for the GTL and Luc ADCC assays (week 20 and week 34 samples, respectively) after the activity observed before immunization was subtracted (after background subtraction). We also calculated the area under the curve (AUC) of ADCC activity versus serum dilution for the responses observed using each assay after background subtraction. For the Luc ADCC assay, the AUC was calculated above a 10% cutoff.
Statistics. Statistical analysis was performed using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA). Analysis among groups was performed using an independent t test or a Mann-Whitney test, depending on the normalcy of data, when two groups were being compared and an analysis of variance (ANOVA) when three groups were being compared. A P value less than 0.05 was considered statistically significant.
RESULTS
In this study, we characterized cellular and humoral responses induced by a highly optimized DNA prime and adjuvanted recombinant protein boost in RhMs. To address if multiple consensus Env immunogens are able to broaden vaccine-induced responses, two different priming immunizations were used. One group of five RhMs received four doses of pHIV Gag, Pol, and consensus clade B Env gp140 DNA at weeks 0, 6, 12, and 18, followed by an SF162 (clade B) gp140 protein boost formulated in MF59 (adjuvanted protein) at week 32. Another group of five received a multi-Env (ME) DNA prime consisting of four doses of pHIV Gag and Pol and consensus clade A, B, C, D, and A/E Env gp140 DNA at weeks 0, 6, 12, and 18, followed by the same protein boost. Four RhMs received the adjuvanted protein only at week 32. All of the consensus DNA immunogens were created as previously described and included RNA and codon optimization as well as efficient IgE leader sequence (29) . All constructs were formulated together in water and delivered in a single intramuscular immunization followed by adaptive EP, as previously described (29) .
We first assessed how increasing the breadth of the prime immunization impacts cellular immune responses using multiparameter flow cytometry. Peripheral blood mononuclear cells (PBMCs) were stimulated overnight with overlapping Gag, Pol, Env A, Env B, Env C, and Env D peptides, and the total response was calculated as the percentage of cells making gamma interferon (IFN-␥), interleukin-2 (IL-2), or tumor necrosis factor alpha (TNF-␣). Following four DNA primes, we observed strong T-cell responses induced by both the clade B-only and the ME primes (Fig. 1A and B and Table 1 ). The inclusion of additional Env plasmids did not further enhance the magnitude of the response. The total CD8 ϩ response to all antigens is comparable at 0.87% Ϯ 0.38% for a clade B prime and 0.87% Ϯ 0.27% for the ME prime. In addition to CD8 ϩ responses, the synthetic DNA prime was also capable of inducing robust CD4 ϩ responses averaging 0.47% Ϯ 0.15% for a clade B prime and 0.48% Ϯ 0.13% for the ME prime. There was a shift in the frequencies of Env responses, with the clade B-only immunization inducing 0.09% of CD4 ϩ and 0.10% of CD8 ϩ T-cell responses compared to 0.40% and 0.74%, respectively, for the ME DNA vaccination. Thus, within the ME DNA responses, Env accounts for 84% and 85% of CD4 ϩ and CD8 ϩ responses, respectively, in contrast to clade B-only immunization, where Gag and Pol responses dominate. Following a clade B recombinant protein (SF162) boost, clade B CD4 ϩ T-cell responses were significantly enhanced from the post-DNA prime level for the clade B-only prime (P Ͻ 0.05) and trended up in the ME prime compared to preboost levels (P ϭ 0.06) (Fig. 1C) . The postboost CD4 ϩ T-cell levels were also significantly higher for the clade Bprimed RhMs than for RhMs boosted with protein only (P Ͻ 0.05) and trended toward an increase in the ME-primed RhMs (P ϭ 0.09). The protein boost was able to slightly affect the CD8 ϩ clade B-specific responses in the clade B Env-only-primed RhMs but not in the ME group (Fig. 1D) .
We hypothesized that these CD4 ϩ responses would provide sufficient T-cell help for the induction of functional antibody responses. To assess the induction of antibodies with a single-Env versus ME prime, we first determined the magnitude and breadth of antibody binding. The ME DNA prime induced higher and broader binding antibody responses than a clade B prime alone (Fig. 2) . After just two doses of ME DNA, all five animals produced antibodies which were able to bind clade A, B, and C HIV-1 Env gp120 proteins, whereas no Env-binding antibodies were detected in sera from animals given two doses of the clade B DNA prime. Animals receiving the clade B DNA prime required the protein boost before all five animals produced clade B-binding gp120 antibodies as well as cross-reactive clade A-and C-binding antibodies. Priming with the ME DNA strategy significantly enhanced binding titers against all three Envs after two, three, and four immunizations compared to results with the single clade B DNA vaccination. Additionally, ME prime-boost was significantly elevated from both the clade B prime-boost (P Ͻ 0.01 for clade A and B gp120) and recombinant protein alone (P Ͻ 0.01 for all gp120s) following the protein boost at week 32. Although the adjuvanted protein boost was an SF162 clade B protein, we still observed an enhancement in clade A and C binding titers primed with ME DNA. Though these binding antibody responses did wane in the memory phase, we were still able to detect high binding titers 11 weeks after protein boost, with the ME DNA prime-protein boost group having the highest levels.
Having observed enhanced binding titers with the ME prime, we wanted to further understand the binding epitopes recognized by the induced antibodies. We first tested the ability of antibodies to bind to various primary gp120 and gp41 proteins (Fig. 3) . After the DNA priming immunizations, the ME group had high binding antibodies to all gp120 Envs tested, which spanned clades A, B, C, 
FIG 2 ME DNA vaccination induces increased binding titer responses compared to levels with single-Env immunization. Responses were measured 2 weeks after
each immunization and 11 weeks after protein boost (memory). Vaccine groups were pGag/Pol/Env B prime-gp140 boost (clade B DNA), pGag/Pol/Env A, B, C, D, and A/E prime-gp140 boost (ME DNA), or recombinant gp140 (rgp140) boost alone. Endpoint binding titers against consensus clade A, clade B, and clade C gp120 were determined following each immunization and memory time point. Horizontal brackets represent significant differences as determined by modified ANOVA between groups at a given time point (*, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001). Horizontal bars represent means.
and A/E. These responses with ME DNA only were either above or at the same level as those of the protein-only control group ( Fig.  3A and B) . When the binding antibodies specific to the gp41 region of HIV Env were analyzed, the DNA-only groups induced a lower level of binding than the protein-only controls (Fig. 3C) . After the protein boost, gp41-specific antibodies were expanded to levels above those of the DNA-only groups. We did see an increase in binding across multiple different Envs in the clade B DNA prime-protein boost group, but these levels were still lower than those of the ME prime-protein boost and reflected more closely the levels of protein-only immunization. Recently, two key areas in the gp120 protein have been found to be important in vaccine protection. Antibodies binding to both V1/V2 and V3 regions contributed to the moderate efficacy of the RV144 trial (14, 35, (41) (42) (43) (44) . Therefore, antibody binding to V1/V2 and V3 epitopes was assessed after DNA prime-protein boost or after protein-only immunization (Fig. 4) . The V1/V2-gp70 fusion proteins carrying the following V1/V2 sequences were tested: strain A2 clade B, consensus A, consensus C, and consensus A/E. Minimal ELISA binding activity (at a serum dilution of 1:35) was noted with the strain A2 clade B-V1/V2 fusion protein using postboost sera from RhMs that received the prime-boost regimens (data not shown). However, there was substantial reactivity (2-to 40-fold increase in OD values) in the sera of all animals during the immunization regimen against cyclic V3 peptides carrying the sequences of consensus A and C as well as the sequence of clade B strain MN (Fig. 4) . Importantly, immunization with ME DNA induced levels of binding similar to those of the protein-only control group. These levels were increased significantly when ME DNA was followed by protein boost (P Ͻ 0.001 compared to preboost levels), inducing antibody levels higher than those with DNA or protein-only immunizations. To further define the specificity of the antibody binding, we mapped linear epitopes within the V3 loop using overlapping 15-mer peptides derived from the consensus clade C Env (Fig. 5A) . Using a serum dilution of 1:50, we observed the strongest binding to the peptide that spans the V3 crown (peptide 9261) in the sera of animals immunized with the ME DNA prime-protein boost (Fig. 5B) . The sera were also able to bind to a peptide that contained the N-terminal ␤-sheet and the crown of V3 (peptide 9259).
In order to further characterize the humoral responses induced by the DNA prime-protein boost regimen, we investigated how the antibody avidity to consensus clade A, B, and C gp120s changed over time. The ability to induce highly avid antibody has been shown to be a correlate of protection in NHPs (45) and is especially important in a prophylactic HIV vaccine where Env density is low, potentially preventing the possibility of bivalent binding (46) . Due to the low antibody titers after DNA vaccination with the clade B-only regimen, antibody avidity was determined using only the ME DNA group (Fig. 6A) . The avidity indexes for clades A, B, and C increased, though not significantly, after the second and third immunizations. After the fourth immunization, the avidity index against clade B gp120 increased to significantly higher levels (P Ͻ 0.05) than after the second immunization. For clades A and C gp120s, however, the avidity indexes after the fourth DNA immunization were slightly lower than the value after the third. Upon protein boosting, the avidity indexes for all clades increased to close to 100, which is significantly higher than levels after the second, third, and fourth immunizations, and these levels were maintained into memory. The avidity indexes after protein boost were compared across clade B DNA-only prime, ME prime, and protein-only immunizations. The ME prime resulted in a significantly higher avidity index after protein boost than that with clade B-only immunization (clade A gp120, P Ͻ 0.001; clade C gp120, P Ͻ 0.01) and protein-only immunization (clade A gp120, P Ͻ 0.0001; clade B gp120, P Ͻ 0.0001; clade C gp120, P Ͻ 0.0001) (Fig. 6B) . Interestingly, for the clade B gp120, even with the small amount of binding antibodies after DNA-only vaccination, the clade B-only DNA prime induced significantly higher avidity after clade B protein boost than protein-only immunization (P Ͻ 0.01). Memory responses were also investigated, and for both the clade B DNA prime-protein boost and the protein-only immunization, the avidity indexes were increased at the memory time point compared to the levels at 2 weeks after vaccination (Fig. 6C) . For all clades, at the memory time point, the avidity indexes were significantly higher for the ME prime-protein boost group than for the clade B-only prime-boost and proteinonly groups. Since the avidity indexes for the ME DNA primeprotein boost at 2 weeks postvaccination and memory time points were close to 100, we also investigated at which dilution the avidity index began to decline (see Fig. S1A and B in the supplemental material). When serum was diluted 4-fold less, the avidity index was slightly decreased and continued to drop down at each subsequent dilution. The avidity index curves for responses at both 2 weeks post-protein boost and memory were similar, suggesting that these levels are maintained but not necessarily increased.
Having characterized the binding antibodies, we next sought to determine how DNA, protein, and a combined DNA prime-protein boost compared for the induction of neutralizing antibodies. Neutralizing titers were measured 2 weeks following the final immunization using the TZM-bl assay against clade A/E, B, and C tier 1 Env-pseudotyped viruses. We observed cross-clade neutralizing antibodies after the ME DNA prime-protein boost in contrast to results with either ME DNA or protein delivered alone (Fig. 7A) . In fact, all five ME DNA prime-protein boost animals had neutralizing titers to MN.3 and MW965.26 that averaged 2 orders of magnitude higher than titers induced with ME DNA alone. After protein boost, the neutralization titers against MN.3 (ID 50 range, 337 to 4434) were significantly higher (P Ͻ 0.05) than those to DNA only (ID 50 range, 45 to 192) and protein-only immunization (ID 50 , baseline). Similar trends were seen with MW965.26 pseudotyped virus, where neutralization titers induced by ME prime-protein boost (ID 50 range, 256 to 9379) were increased, though not significantly, compared to those with DNA only (ID 50 range, 67 to 280) (P Ͻ 0.13) and protein only (ID 50 range, baseline to 27) (P Ͻ 0.1). Animals immunized with ME DNA alone or with ME DNA prime-protein boost had low neutralizing responses to the clade A/E TH023.6 pseudovirus (ID 50 ranges were as follows: ME DNA, baseline to 177; ME plus protein, baseline to 1,897; protein only, baseline). A single dose of gp140 protein alone resulted in essentially no neutralizing antibodies to any of the three pseudoviruses tested. These neutralization titers waned in the memory phase, with ME DNA prime-protein boost having levels below 10 2 for all three pseudotyped viruses. Lastly, we examined the ability of the different vaccine platforms to induce functional antibody responses capable of inducing antibody-dependent cellular cytotoxicity (ADCC) as an indication of the induced Fc-mediated Ab functions capable of recognizing infected cells. We analyzed samples using HIV-1 clade B SF162 gp120-coated cells, homologous to the recombinant protein boost (36) . We observed significantly higher ADCC values, measured as both maximal percent GzB activity and percent GzB activity (AUC) (Fig. 7B and C) , in animals that received the ME DNA prime-protein boost than those in animals receiving DNA alone (P Ͻ 0.05) or protein alone (P Ͻ 0.01). We next evaluated the ADCC response using HIV-1 SF162-infected target cells (luciferase ADCC assay). The responses detected for the ME DNA prime-protein boost group were higher than those of the other two groups; however, these differences did not reach statistical significance ( Fig. 7D and E) .
DISCUSSION
There is a critical need for an effective HIV vaccine to induce helper cells to support cytotoxic T-cell responses that can kill virus-infected cells, as well as providing strong B-cell help required for the maturation of antibodies and induction of B-cell memory. The delivery of consensus Env DNAs from multiple clades can enhance the breadth of the T-cell response, which could help avoid T-cell escape upon infection. By using the consensus Envs, a DNA vaccine is able to specifically encode conserved T-cell epitopes which could be included in many different strains. Importantly, the robust responses generated with a synthetic DNA prime were efficiently boosted by the administration of an adjuvanted recombinant protein. While CD4 ϩ T-cell responses were more effectively boosted with protein, modest boosting of CD8 ϩ T cells was also observed, especially in the animals receiving only the clade B prime, where a larger percentage of the T-cell response was matched to the clade B recombinant boost.
In addition to robust T-cell responses, in this study we observed for the first time the ability of synthetic DNA to induce high titers of binding antibodies, similar to protein vaccine platforms which have been characterized as being able to induce strong humoral responses (47) (48) (49) . Though the clade B-only group induced lower humoral responses, this was not due to lower protein expression as both CD4 ϩ and CD8 ϩ T-cell responses against clade B Env peptides was higher in the B-only group than those in the ME DNA immunization group (CD4 ϩ , 0.087% versus 0.046%; CD8 ϩ , 0.102% versus 0.064%, respectively) ( Table 1) . These data also suggest that an ME DNA prime can elicit a broad humoral response and that both heterologous and homologous responses can be boosted with a single recombinant protein. In addition, we observed lower gp41 binding after four doses of DNA immunizations than binding after a single dose of recombinant gp140 Env (Fig. 3C) . Though preliminary, this suggests that the DNA vaccination focused the humoral responses to the gp120 region of Env, whether it was delivered in a full-length or truncated gp140 form. This response could be due to the antigen being presented on the surface of transfected cells, leading to less exposure of the gp41 region than with recombinant free protein. Additionally, the avidity index of humoral responses is significantly higher when RhMs are primed with DNA followed by protein boost than that with a single protein immunization (Fig. 6) . Even for the group immunized with clade B-only DNA, the avidity to consensus clade B gp120 is significantly higher after protein boost than that with the protein-only immunizations. This suggests that DNA vaccination could be inducing adequate help, which is expanded upon boosting with protein. The functional antibody response observed was qualitatively similar to the binding antibody response with the ME DNA prime-protein boost, inducing higher neutralizing and ADCC titers than either platform alone (Fig. 7) . The ability to boost with multiple protein Envs may further increase antibody breadth, titers, and potency. Studies investigating differences between heterologous/homologous prime-boost immunizations containing multiple Envs are of interest, and this study provides a strong rationale for these.
The ability to induce humoral responses to specific portions of the HIV Env could increase the protective efficacy of the vaccine regimen. In the case of the modestly successful RV144 trial, these antigenic regions include the V1/V2 region as well as the V3 region. We detected minimal to no vaccine-induced antibodies to V1/V2 fusion proteins. These responses may not have been adequately primed by the DNA immunization nor further expanded by the adjuvanted protein immunization. Even though there was limited V1/V2 binding, we did observe substantial induction of antibody binding to the V3 region of clades A, B, and C (Fig. 4) . These responses were highest in the ME DNA prime-protein boost-immunized group. Analysis of the RV144 trial demonstrated that antibodies against V3 inversely correlated with risk of infection in a subpopulation of vaccine recipients who had low levels of serum IgA Env-specific antibodies (44) . Additional analysis revealed that these antibodies would be able to exert immune pressure against the virus (35) . The antibodies were found to predominately bind to a region that included the I 307 amino acid, which is a key contact point for many V3 binding antibodies (50) (51) (52) . This amino acid is maintained within our peptides used for linear mapping and is included in the two peptides that indicated the highest binding. Though glycan-independent V3 antibodies are less broad and potent in their neutralization capacity than the glycan-dependent V3 antibodies, the former have been shown to be important in reducing infection in the RV144 trial and in providing sterilizing protection in passive transfer challenges (53) (54) (55) (56) . Thus, the ability for a vaccine to induce such antibodies may be important for protection.
The improved immunogenicity seen within this study is achieved in the absence of employing immune plasmid adjuvants to increase vaccine-induced responses. The inclusion of molecular adjuvants such as IL-12, IL-28, or CCL28 may further enhance the cellular and humoral responses achieved by a synthetic DNA prime (27, 32, (57) (58) (59) (60) . Potentially, the inclusion of one of these plasmid adjuvants could help increase memory responses, leading to the maintenance of neutralizing antibodies. Additionally, novel delivery devices such as intradermal electroporation have shown promising preclinical results and the ability to induce improved humoral responses (22, 26, 61) . Lastly, boosting with more than one dose of recombinant protein, protein from multiple clades, or recombinant epitope-scaffold proteins that focus the immune response on particular regions of the Env, as well as the use of alternative adjuvants, may further improve the breadth, magnitude, and maintenance of the HIV-specific response. These results merit future preclinical evaluation to further test the limits of polyvalency from more potent DNA constructs on inducing anti-HIV immune responses. Improved DNA primes may The avidity index of humoral responses against consensus clade A, B, and C gp120 was determined 2 weeks after each immunization and into memory for the ME DNA prime-protein boost group (A). The avidity index was also analyzed 2 weeks after protein boost (B) and at a memory time point (C) for all three groups against consensus clade A, B, and C gp120. Horizontal brackets represent significant differences as determined by modified ANOVA between groups at a given time point (*, P Ͻ 0.05; **, P Ͻ 0.01; ***, P Ͻ 0.001; ****, P Ͻ 0.0001). Horizontal bars represent means.
be combined with multiple platforms in order to improve platform performance. after the ME DNA prime and ME DNA prime-protein boost and into memory. Neutralization titers were also determined for protein-only immunizations at 2 weeks after vaccination and into memory. ADCC was analyzed 2 weeks following the ME DNA prime, ME DNA prime-protein boost, or protein boost alone. The maximal percent specific granzyme B activity (B) and area under the curve (AUC) granzyme B activity (C) were determined using the GTL assay with SF162-coated targets. Background (preimmunization) activity was subtracted from each measurement. The maximal percent specific killing (D) and AUC specific killing (E) were determined using a luciferase assay with infected CD4 ϩ target cells. The values represent percent specific killing after baseline correction. Bars represent means, with error bars representing standard errors. Significance was determined using modified ANOVA (*, P Ͻ 0.05; **, P Ͻ 0.01).
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